- ViiV Healthcare and Medicines Patent Pool (MPP) have signed sublicence agreements with Aurobindo Pharma, Cipla Limited, and Viatris Inc (NASDAQ:VTRS) – through its subsidiary Mylan – to manufacture generic versions of cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP).
- Aurobindo Pharma and Viatris will manufacture in India.
- Cipla Limited will manufacture in India and plans to manufacture in South Africa too.
- ViiV Healthcare is majority owned by GSK Plc (NYSE:GSK), with Pfizer Inc (NYSE:GSK) and Shionogi as shareholders.
- GSK said in a statement that approximately 1.5 million people acquired HIV worldwide in 2021, among whom 860,000 live in sub-Saharan Africa. While oral PrEP options are now available in many countries, access to cabotegravir LA for PrEP could significantly contribute to reducing HIV transmission by providing people with a choice in their HIV prevention options.
- In July 2022, ViiV signed a new voluntary licensing agreement with the Medicines Patent Pool (MPP) for patents relating to cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP) for the least developed, low-income, lower-middle-income and Sub-Saharan African countries.
- The agreement allowed selected generic manufacturers to develop, manufacture and supply generic versions of long-acting cabotegravir for PrEP, the first long-acting HIV prevention medicine, in 90 countries, subject to regulatory approvals.
- In December 2021, the FDA approved ViiV Healthcare’s Apretude, the first and only long-acting injectable pre-exposure prophylaxis option, to reduce the risk of sexually acquired HIV-1.
- The long-acting injectable was approved for use in adults and adolescents weighing at least 35 kg who are at risk of sexually acquiring HIV and have a negative HIV-1 test before initiation.
What’s Going On With SoFi Technologies Stock After Earnings?
Despite the better-than-expected results, Sofi shares are dipping lower Tuesday after falling 10% on Monday. Following the print, Wedbush analyst David Chiaverini reiterated Sofi with an Underperform and maintained a $3 price target on the stock. Needham reiterated its Buy rating and maintained a $10 price target.
